Literature DB >> 17181563

N-terminal pro-brain natriuretic peptide used for the prediction of coronary artery stenosis.

T Wolber1, M Maeder, H Rickli, W Riesen, C Binggeli, F Duru, P Ammann.   

Abstract

BACKGROUND: The level of the inactive N-terminal fragment of pro-brain (B-type) natriuretic peptide (NT-proBNP) is a prognostic marker in patients with acute and chronic coronary artery disease (CAD). It might also be valuable for non-invasive diagnosis of coronary artery disease.
MATERIALS AND METHODS: The NT-proBNP was measured in 781 consecutive patients with normal left ventricular function referred for coronary angiography owing to symptoms or signs of CAD. The diagnostic value of NT-proBNP was assessed for predicting CAD at angiography.
RESULTS: Elevated NT-proBNP levels were associated with the extent of CAD and with the female sex (P < 0.001). The ability of NT-proBNP to predict significant coronary disease at angiography was assessed separately for men using a cut-off point of 85 pg mL(-1), positive likelihood ratio 2.2 (95% CI, 1.7-3.0), negative likelihood ratio 0.53 (95% CI 0.45-0.63) and area under the receiver-operating-characteristic (ROC) curve 0.72: for women, it was assessed using a cut-off point of 165 pg mL(-1), positive likelihood ratio 2.4 (95% CI, 1.7-3.4), negative likelihood ratio 0.55 (95% CI, 0.44-0.70) and area under ROC curve 0.71. In multiple logistic-regression analysis, NT-proBNP added significant independent predictive power to other clinical variables in models predicting CAD (odds ratio 2.76, 95% CI, 1.76-4.32, P < 0.001).
CONCLUSIONS: The NT-proBNP is a marker of non-obstructive CAD and of significant coronary stenosis. In conjunction with other clinical information, measurement of NT-proBNP with the use of sex-specific reference ranges may improve the non-invasive prediction of CAD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17181563     DOI: 10.1111/j.1365-2362.2007.01731.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  9 in total

1.  Hypoxia regulates the natriuretic peptide system.

Authors:  Olli Arjamaa; Mikko Nikinmaa
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-09-07

2.  A slightly elevated level of N-terminal pro-brain natriuretic peptide can predict coronary artery disease in a population with normal left ventricular function.

Authors:  Nobutaka Ikeda; Masato Nakamura; Yoshiyuki Yazaki; Tsuyoshi Ono; Masaya Yamamoto; Shingo Ito; Itaru Yokouchi; Suguru Yajima; Raisuke Iijima; Hidehiko Hara; Takuro Takagi; Hisao Hara; Toshiyuki Asahara; Hideyuki Sakai; Kaoru Sugi
Journal:  Heart Vessels       Date:  2010-11-26       Impact factor: 2.037

Review 3.  Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases.

Authors:  Da-Rong Pu; Jun R Chiong; Qi-chang Zhou
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

4.  NCF2, MYO1F, S1PR4, and FCN1 as potential noninvasive diagnostic biomarkers in patients with obstructive coronary artery: A weighted gene co-expression network analysis.

Authors:  Xian-Gang Mo; Wei Liu; Yao Yang; Saber Imani; Shan Lu; Guorong Dan; Xuqiang Nie; Jun Yan; Rixing Zhan; Xiaohui Li; Youcai Deng; Bingbo Chen; Yue Cai
Journal:  J Cell Biochem       Date:  2019-06-27       Impact factor: 4.429

5.  Angiopoietin-2 provides no incremental predictive value for the presence of obstructive coronary artery disease over N-terminal pro-brain natriuretic peptide.

Authors:  Wen Jian; Chang-Hua Mo; Guo-Liang Yang; Lang Li; Chun Gui
Journal:  J Clin Lab Anal       Date:  2019-07-01       Impact factor: 2.352

Review 6.  Extracellular Vesicles in Diagnosing Chronic Coronary Syndromes the Bumpy Road to Clinical Implementation.

Authors:  Mirthe Dekker; Farahnaz Waissi; Nathalie Timmerman; Max J M Silvis; Leo Timmers; Dominique P V de Kleijn
Journal:  Int J Mol Sci       Date:  2020-11-30       Impact factor: 5.923

7.  Editorial: Smoldering Inflammation in Cardio-Immune-Metabolic Disorders.

Authors:  Gilda Varricchi; Nazareno Paolocci; Felice Rivellese; Giuseppe Rengo
Journal:  Front Physiol       Date:  2021-03-19       Impact factor: 4.566

8.  Physical performance and glycemic control under SGLT-2-inhibitors in patients with type 2 diabetes and established atherosclerotic cardiovascular diseases or high cardiovascular risk (PUSH): Design of a 4-week prospective observational study.

Authors:  Devine S Frundi; Eva Kettig; Lena Luise Popp; Melanie Hoffman; Marine Dumartin; Magali Hughes; Edgar Lamy; Yvonne Joko Walburga Fru; Arjola Bano; Taulant Muka; Matthias Wilhelm
Journal:  Front Cardiovasc Med       Date:  2022-07-22

9.  Clinical correlation between N-terminal pro-B-type natriuretic peptide and angiographic coronary atherosclerosis.

Authors:  Demóstenes G L Ribeiro; Ricardo P Silva; Daniella R M M Barboza; Roberto C P Lima-Júnior; Ronaldo A Ribeiro
Journal:  Clinics (Sao Paulo)       Date:  2014-06       Impact factor: 2.365

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.